PFA Pension Forsikringsaktieselskab Makes New $88 Million Investment in Medtronic PLC $MDT

Key Points

• PFA Pension Forsikringsaktieselskab opened a new position of 910,421 shares in Medtronic in Q4, a purchase valued at approximately $88 million that represents about 0.07% of the company.
• Medtronic slightly beat Q4 estimates with $1.36 EPS and $9.02 billion in revenue and set FY2026 guidance of $5.62–$5.66 EPS; the company pays a $0.71 quarterly dividend (annualized yield ~3.5%).
• Institutional ownership is high at 82.06% and analysts have a consensus "Moderate Buy" with a $107.80 target, but the stock trades near 12‑month lows (~$80) despite recent product wins like the Stealth AXiS CE mark and other regulatory approvals that could drive growth.

PFA Pension Forsikringsaktieselskab purchased a new position in shares of Medtronic PLC (NYSE:MDT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 910,421 shares of the medical technology company's stock, valued at approximately $88,001,000. PFA Pension Forsikringsaktieselskab owned approximately 0.07% of Medtronic as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Syntax Research Inc. grew its holdings in Medtronic by 2.2% during the 4th quarter. Syntax Research Inc. now owns 6,979 shares of the medical technology company's stock worth $670,000 after acquiring an additional 151 shares in the last quarter. New England Capital Financial Advisors LLC grew its holdings in Medtronic by 7.8% during the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company's stock worth $135,000 after acquiring an additional 101 shares in the last quarter. Fifth Third Bancorp grew its holdings in Medtronic by 0.6% during the 4th quarter. Fifth Third Bancorp now owns 201,581 shares of the medical technology company's stock worth $19,364,000 after acquiring an additional 1,253 shares in the last quarter. Danske Bank A S grew its holdings in Medtronic by 11.5% during the 4th quarter. Danske Bank A S now owns 841,228 shares of the medical technology company's stock worth $80,808,000 after acquiring an additional 86,433 shares in the last quarter. Finally, Mutual Advisors LLC lifted its position in shares of Medtronic by 2.0% during the 4th quarter. Mutual Advisors LLC now owns 43,552 shares of the medical technology company's stock worth $4,184,000 after buying an additional 850 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Stock Down 1.2%

MDT stock opened at $80.02 on Friday. The company has a fifty day moving average price of $88.44 and a 200 day moving average price of $94.82. Medtronic PLC has a 12 month low of $78.91 and a 12 month high of $106.33. The company has a market cap of $102.74 billion, a price-to-earnings ratio of 22.29, a price-to-earnings-growth ratio of 2.10 and a beta of 0.62. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. Medtronic's revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts expect that Medtronic PLC will post 5.57 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were given a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.5%. Medtronic's dividend payout ratio is 79.11%.

Analyst Ratings Changes

Several analysts have recently weighed in on MDT shares. Citigroup reduced their price objective on shares of Medtronic from $117.00 to $110.00 and set a "buy" rating for the company in a research report on Tuesday, April 7th. Evercore set a $106.00 price objective on shares of Medtronic and gave the stock an "outperform" rating in a research report on Thursday, April 9th. Leerink Partners restated an "outperform" rating and set a $119.00 price objective on shares of Medtronic in a research report on Tuesday, March 10th. Stifel Nicolaus reduced their price objective on shares of Medtronic from $105.00 to $95.00 and set a "hold" rating for the company in a research report on Monday, April 6th. Finally, Mizuho reduced their price objective on shares of Medtronic from $125.00 to $120.00 and set an "outperform" rating for the company in a research report on Monday, April 13th. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $107.80.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next‑generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere‑9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed‑field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next‑generation mitral valve, and Medtronic has enrolled the first patient in a post‑approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long‑term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company‑specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real‑world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi‑month/1‑year lows highlights investor concern about valuation and near‑term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.